Preclinical studies have shown that therapeutic PD-1 cancer vaccines are safe and effective

A study led by researchers at Ohio State University's Comprehensive Cancer Center describes a potential therapeutic cancer vaccine that releases inhibitory immune cells that kill cancer so they can attack and destroy tumors.
, published October 1, 2020 in the journal Oncology Immunology, showed that the peptide, called PD1-Vaxx, was the first checkpoint inhibitor vaccine and was safe and effective in animal models of colon cancer.
the vaccine produces multiclonal antibodies that inhibit the programmed cell death of PD-1 on cancer cells.
researchers say the vaccine mimics the role of the PD-1 inhibitor, opdivo, but avoids triggering resistance associated with the drug.
found that PD1-Vaxx is effective in inhibiting tumor growth.
is even more effective when used in combination with another therapeutic peptide vaccine, two bits on the HER-2 subject that targets colon cancer cells.
. Pravin T. P. Kaumaya, lead author of the study, said, "There are two key reasons why our study is important.
, PD1-Vaxx activates B-cell and T-cell functions to promote tumor removal.
, the goal of the treatment is to block the signaling path paths that are essential for tumor growth and maintenance."
。